BREAKING: 7x Midas Investor… | Sourcery Newsletter Summary

1. Key Themes

Theme 1: AI Drug Discovery Has Hit an Inflection Point

The last two years changed what AI can produce in biology

Lamont's firm watched AI in life sciences for a decade before committing, because it wasn't yielding real drug candidates until recently.

"We've been looking at AI for the last decade and had not seen it produce more developable products, therapeutics. And everything's changed the last 2 years."

LLM infrastructure unlocked industry-specific biology and chemistry models

"LLM infrastructure made it possible to build biology and chemistry models specific to the industry, and physical AI and lab robotics followed."

Simulation is expected to reshape the entire drug development chain

"Drug development is the most expensive product development process of any industry, and it has the highest failure rate... Lamont expects simulation to reshape every step from design through clinical trials."

Chai Discovery's roadmap illustrates the commercial potential

"Lamont says Chai's antibody work makes a lab about 100x more productive than one without it." Chai-2 "reached double-digit experimental success rates, a 100-fold gain over earlier computational methods," and Eli Lilly was named as its first pharma customer.

Theme 2: China Is a Direct Competitive Threat to US Biopharma

Pharma's outside research dollars are shifting to China

"Pharma in the last 4 years has 50% of the outside dollars they're spending on research are going to China. That was not the case 5 years ago."

Licensing data corroborates the shift

"Goldman Sachs Research found China accounted for about half of global licensing deals by dollar value... GlobalData puts China's 2025 out-licensing value at $115B, with almost half of all US in-licensing now coming from China."

Research output and supply chain are secondary risks

"On the research side, they have as many or more patents now coming out of university and out of their research arms as we have." She also cited COVID, "when China produced 90% of the ingredients for antibiotics," and NIH funding cuts to US universities, which she calls "the bedrock of US drug discovery."

Regulatory reform is part of her prescription

"Lamont says the US has put too much weight on safety relative to efficacy... She called for a complete re-engineering of the FDA and its processes, starting with life-saving drugs."

Theme 3: AI as a Horizontal Layer Applied to Deep Vertical Workflows

Healthcare + fintech cover half the economy, giving Oak buyer-side knowledge

"Together, Oak's healthcare and fintech practices cover about 50% of the economy. That reach gives Oak direct knowledge of the companies that buy from AI startups."

Healthcare is a concentrated, knowable market

"It's the smallest large market you've ever seen in that it's 100 providers that matter."

AI's advantage is depth within horizontal products

"What's the advantage of AI? That you can create a horizontal product that actually works in a deep way with workflows or specifically in a particular industry."

Theme 4: AI Attacking Healthcare's Administrative Burden

Administrative work is the prize

"She puts administrative work at 25% to 30% of all US healthcare costs. She sees AI as the first technology to take that work off clinicians."

Care delivery changes, not just costs

"Their clinician will not be behind a laptop now. Will not have their back turned to them while they're inputting data."

Augmentation, not replacement, in radiology

"She also says 30% of radiology images are read with something missed... she expects the field to need more radiologists, not fewer."

Devoted Health as the proof point

"Over the last year, Devoted tripled in size, cut its operating ratio in half, and grew EBITDA." Lamont: "It is probably the best example of AI applied to healthcare in the world right now."

Theme 5: The Healthcare Exit Landscape Is Widening

Frontier labs and hyperscalers are emerging as buyers

"Frontier AI labs are now possible buyers of healthcare software. Lamont pointed to Microsoft's acquisition of Nuance and Oracle's acquisition of Cerner as earlier examples. Her main worry for Chai is that a frontier lab or hyperscaler buys it."

Small companies are merging earlier

"There are a lot of smaller companies that realize they're a product and not a company."

Acquisition success depends on how acquirers treat people

"If you want product to evolve, then you probably need to figure out how to inspire a team or keep them separate." She contrasted JPMorgan (best people from both sides in senior roles) with Credit Suisse (favored its own staff).

2. Contrarian Perspectives

Only ~10% of AI companies justify current valuations, even from a bullish AI investor

Lamont is simultaneously extremely bullish on AI's economic impact and skeptical of most valuations.

"I just think you've got 10% of the world that's worth it and 90% that's not."

Supporting evidence: "Many niche AI companies will still top out at $1B to $2B in value. An AI version of TPA software, for example, will most likely be bought on EBITDA." She expects inflated valuations to correct "as they always have," while still saying: "There's nothing been as interesting as this or seminal in terms of realigning the entire economy."

Hospitals aren't going away; AI helps clinicians rather than displacing institutions

Against the narrative that AI disrupts hospital systems, she expects them to stay central to acute care.

"Lamont expects hospital systems to remain central to acute care." On radiology: "she expects the field to need more radiologists, not fewer."

The venture bar for founders is too low

Despite abundant capital, she argues standards should be higher than past cycles.

"The bar for your entrepreneurs is not high enough." Reasoning: "markets move faster and more capital is chasing more companies," and today's product-led founders must show they "understand go-to-market and will hire the right people around them."

3. Companies Identified

Chai Discovery

Description: AI drug design company (antibodies → peptides → small molecules), founded by Joshua Meier and Jack Dent.
Why mentioned: Oak's flagship AI life sciences bet; Lamont sits on the board.
Quotes: "Jack and Josh, this may be a company for the ages." "In December 2025, Oak HC/FT and General Catalyst co-led Chai's $130M Series B at a $1.3B valuation... In January 2026, Chai named Eli Lilly as its first pharmaceutical customer."

Devoted Health

Description: Medicare Advantage plan with its own tech platform and primary care medical group, founded 2017 by Ed and Todd Park.
Why mentioned: Cited as the best AI-in-healthcare example and a payer-provider model superior to Kaiser.
Quotes: "It is probably the best example of AI applied to healthcare in the world right now." "Devoted tripled in size, cut its operating ratio in half, and grew EBITDA. The company plans to move into commercial insurance."

Auger

Description: AI supply chain platform founded with Dave Clark (ex-Amazon).
Why mentioned: Example of Oak building a company from the idea stage with a $100M day-one commitment.
Quotes: "This is real time analytics on everything that's going on in your supply chain, and then an agent that can actually act on it immediately." "Total funding is now $150M... customers include Meta, Fanatics, and Kimberly-Clark... his goal is more than $1B in revenue by 2030."

Halluminate

Description: Builds reinforcement learning environments to train AI agents on financial and economic reasoning (YC S25).
Why mentioned: Fast-growing newer portfolio company selling to AI labs.
Quotes: "Lamont says the company went from 0 to 60 in 6 months and expects it to reach 100 next year." "One environment simulates an entire real estate brokerage."

CareBridge

Description: Home-based care company developed by Oak with Brad Smith.
Why mentioned: Example of a successful exit and repeat-founder model.
Quotes: "Oak and Smith then spent a year developing CareBridge and Main Street Health together, and Elevance later acquired CareBridge."

Main Street Health

Description: Co-developed by Oak and Brad Smith.
Why mentioned: Part of the Brad Smith repeat-founder track record.
Quotes: "Lamont says each Smith company used a model no one else was running."

Aspire Health

Description: Palliative care model brought to Oak by Brad Smith.
Why mentioned: Filled a gap Oak had searched for over years.
Quotes: "Brad Smith brought Oak Aspire Health, a palliative care model, after the firm had looked for one for 15 to 20 years."

athenahealth / Castlight

Description: Healthcare companies co-founded by Todd Park.
Why mentioned: Todd Park's earlier track record.
Quotes: "Todd Park co-founded athenahealth and Castlight, and Oak led Devoted's Series A."

Kaiser

Description: Best-known combined payer-provider.
Why mentioned: Foil to Devoted's model.
Quotes: "In her view, Kaiser has not lowered costs or produced a healthier population."

Oak HC/FT

Description: Healthcare/fintech VC, $14B managed historically, $7B+ currently across 100+ companies; Fund VI of nearly $2B.
Why mentioned: Subject firm.
Quotes: "We want to be a life cycle investor. So we'll invest $1 million, but we often invest that million, sometimes committing $100 million to the company from day one."

Other portfolio companies noted: Ambience Healthcare, Fundamental, Blue J, Candid Health, Akido, Rillet, Stepful, Catena, Curana, Infusion for Health, One Medical, VillageMD, Komodo Health, Cotiviti, Feedzai.

Why mentioned: Oak's newer AI portfolio and historical wins.
Quotes: "Oak's newer AI portfolio includes Chai Discovery, Ambience Healthcare, Fundamental, Blue J, Candid Health, Akido, Rillet, Auger, Stepful, and Catena." "Enterprise tech like Rillet in ERP has a long runway, and so do pharma-facing companies like Chai and Ambience."

Nuance / Cerner (Microsoft / Oracle)

Description: Healthcare software companies acquired by big tech.
Why mentioned: Precedents for tech acquirers in healthcare.
Quotes: "Lamont pointed to Microsoft's acquisition of Nuance and Oracle's acquisition of Cerner as earlier examples."

JPMorgan / Credit Suisse

Description: Banks used as M&A integration case studies.
Why mentioned: Contrast in handling acquired talent.
Quotes: "JPMorgan, which put the best people from either side into senior roles, with Credit Suisse, which favored its own staff."

4. People Identified

Annie Lamont

Description: Co-Founder & Managing Partner, Oak HC/FT.
Why mentioned: Interview subject, 40+ years investing.
Quotes: "Across 40+ years she has managed $14B, backed 70+ successful exits and 15 IPOs, and been named the top healthcare investor on the Forbes Midas List." "I've never learned so much so fast in my entire life."

Andrew Adams

Description: Oak HC/FT co-founder.
Why mentioned: Lamont's partner in decision-making.
Quotes: "She and Andrew Adams work through decisions together and almost always reach the same conclusion."

Todd Park

Description: Serial healthcare founder; Devoted Health Executive Chairman.
Why mentioned: Repeat founder Oak backed twice.
Quotes: "Todd Park co-founded athenahealth and Castlight, and Oak led Devoted's Series A."

Ed Park

Description: Devoted Health CEO.
Why mentioned: Co-founded Devoted in 2017.
Quotes: "Ed is CEO and Todd is Executive Chairman."

Brad Smith

Description: Repeat founder (Aspire Health, CareBridge, Main Street Health).
Why mentioned: Example of a founder Oak backs repeatedly.
Quotes: "Lamont says each Smith company used a model no one else was running."

Joshua Meier and Jack Dent

Description: Chai Discovery founders.
Why mentioned: Lamont's highest praise.
Quotes: "Jack and Josh, this may be a company for the ages."

Dave Clark

Description: Former Amazon supply chain/logistics and e-commerce leader; Auger founder.
Why mentioned: Built Auger with Oak after initially wanting to acquire a company.
Quotes: "Clark spent more than 20 years building Amazon's supply chain and logistics, then ran its e-commerce business."

Jerry Gallagher

Description: Retail investor behind Dick's Sporting Goods, PetSmart, and Office Depot.
Why mentioned: Lamont's early mentor.
Quotes: "Lamont credited Jerry Gallagher with raising her standards early in her career."

5. Operating Insights

Screen founders on intellect, intent, ethics, and "secure not arrogant"

Lamont's diligence begins with the founder and filters hard on character, especially in regulated industries.

"Lamont's first tests are intellect and intent." "It passes on healthcare founders who seem more focused on money than on patient outcomes." "They have to be really secure. Secure people, not arrogant. So secure they'll ask every and any question."

Check that product-led founders can handle go-to-market

"Today's founders tend to be product and tech-led, so Oak checks whether they understand go-to-market and will hire the right people around them." She also looks for "a founder others will follow, someone people will want to work for over 10 years."

Protect the board and plan M&A around people

Board composition matters and so does post-acquisition team treatment.

"We all know that a board can destroy a company." And on acquisitions: "Keeping a product improving means keeping the team motivated, or keeping it separate."

6. Overlooked Insights

Lamont may have been too price-sensitive on some exits

"When Oak sells companies, it generally gets about a 30% premium from strategic buyers. Lamont says Oak may have been too sensitive to price on some deals." This hints that disciplined entry price can cost access to the best companies, and that strategic buyers pay up.

Healthcare's remote surgery and rural outcomes opportunity

"Surgeons or robots directed remotely could also help close the outcome gap between rural patients and those living near leading research hospitals." Briefly mentioned, but it points to a potentially large access and market-expansion opportunity beyond administrative cost savings.